Elekta

SAN DIEGO – Elekta (EKTA-B.ST) today announced that Elekta Unity MR-Linac clinical users presented several abstracts highlighting how the high-field system is pushing the boundaries of radiation therapy. The data were presented as part of the scientific program during the 2023 American Society for Radiation Oncology Annual Meeting (ASTRO) October 1-4 in San Diego, California.
 
Throughout the congress, leading hospitals in the U.S. and Europe shared how using online plan adaptation and Comprehensive Motion Management (CMM) with Elekta Unity have changed the way they treat patients.
 
“This was our first week treating patients with the CMM upgrade with Elekta Unity and I am impressed,” says Daniel Hyer, PhD, Professor of Radiation Oncology at the University of Iowa Health Care. “On a pelvic node, the system gated the beam during unexpected patient motion. On another patient, we were able to perfectly track a target next to the heart despite cardiac and respiratory motion. I fully expect that we will begin treating the majority of our lung cases on the Unity system.”
 
Similarly, Professor Filippo Alongi, Full Professor and Chairman of the Advanced Radiation Oncology department at the IRCCS Ospedale Sacro Cuore Don Calabria in Negrar, Italy, explained how he was able to shrink planning target volume margins on a liver tumor without the need for fiducials or difficult to tolerate breath hold.
 
“With Unity and CMM we will be able to radically change the approach for patients; now we can be precise in a way that was not possible before. With the high-quality imaging and the possibility to interrupt the beam when the target is outside the boundaries, we can eliminate uncertainties of movement allowing us to treat more indications with MRgRT, reduce margins and increase dose. We’re deeply impressed by the innovation of Comprehensive Motion Management and what it will mean for patients,” says Prof. Alongi.
 
Dr. John Christodouleas, SVP of Medical Affairs & Clinical Research at Elekta, also highlighted two additional Elekta Unity abstracts that demonstrate:

• How margins for the treatment of rectal cancer were reduced by a third using Elekta Unity compared to conventional radiotherapy techniques. Rectal treatments captured in the international MOMENTUM registry showed that patients experienced stabilized or improved quality of life over 12 months of follow up. Read about it here.

• How MR-guided SABR to pancreatic oligometastases from renal cell carcinoma is a safe and effective treatment option. In addition, MR-guided SABR may facilitate deferral of systemic therapy initiation in this select group of patients with favorable prognosis. Read about it here.

 Learn more about how you can see clearly, adapt to change and be certain you are delivering the treatment you prescribed at: www.elekta.com/Unity.
 
*Elekta Unity with Comprehensive Motion Management (CMM) has CE mark and U.S. FDA 510(k) clearance. Not available in all markets.
 
# # #
 
For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com  
Time zone: CET: Central European Time
 
Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time
 
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.